Core Points - Sampo plc announced a share buyback program of up to EUR 150 million, which commenced on 6 November 2025 [1] - On 24 November 2025, Sampo plc acquired a total of 205,007 A shares at an average price of EUR 10.04 [1] - Following the transactions, Sampo plc holds a total of 3,085,996 A shares, representing 0.12% of the total shares outstanding [2] Summary by Category Share Buyback Program - The share buyback program is in compliance with the Market Abuse Regulation (EU) 596/2014 and the Commission Delegated Regulation (EU) 2016/1052 [1] - The program was authorized by Sampo's Annual General Meeting on 23 April 2025 [1] Transaction Details - The daily buyback volume on 24 November 2025 included: - 8,735 shares at EUR 10.02 on AQEU - 96,270 shares at EUR 10.04 on CEUX - 24,999 shares at EUR 10.04 on TQEX - 75,003 shares at EUR 10.03 on XHEL [1] Ownership Post-Transaction - After the buybacks, Sampo plc's total ownership of A shares increased to 3,085,996, which is 0.12% of the total shares [2]

Company Overview - Mowi ASA is one of the world's leading seafood companies and the largest producer of farm-raised Atlantic salmon, with an estimated harvest of 605,000 tonnes in 2026 from seven countries [2][3] - The company is headquartered in Bergen, Norway, employs 12,300 people across 26 countries, and is listed on the Oslo Stock Exchange [3] - Mowi reported a turnover of EUR 5.6 billion in 2024 [3] Sustainability and Market Position - Mowi is recognized as the most sustainable listed animal protein producer globally, according to Coller FAIRR [3] - The company operates under its own MOWI brand, providing high-quality salmon and other seafood to consumers worldwide [3] Financial Activities - Mowi has mandated several banks to arrange a series of fixed income investor meetings, indicating potential future NOK-denominated senior unsecured green bond issues, swapped to EUR, with a minimum tenor of 5 years [1][2] - The issuance of these bonds is subject to market conditions [2]

Core Insights - The company reported stable sales growth and improvements in gross margin despite a volatile market environment [1][3] - Total sales for Q3 2025 increased by 4% year-on-year to DKK 289 million, with organic growth of 3% [1][9] - The company is narrowing its full-year 2025 guidance for revenue and adjusted EBIT [6] Sales Performance - Order intake showed high single-digit growth in the core business and double-digit growth in the B2C segment [2] - B2B project orders declined slightly, while orders from builders of turnkey residential houses exhibited a strong positive trend [2] Financial Metrics - Gross margin increased to 21.4% in Q3 2025, up from 20.3% in Q3 2024, driven by higher average selling prices and efficiency gains [3] - Adjusted EBIT remained broadly unchanged at DKK 16.6 million, with an adjusted EBIT margin of 5.8% [4][9] - Free cash flow decreased to DKK 4 million from DKK 6 million in the same period last year, primarily due to adverse working capital developments [5][9] Guidance and Future Outlook - The company expects full-year revenue in the range of DKK 1,260–1,280 million and adjusted EBIT in the range of DKK 93–100 million [6][15] - TCM Group will take full ownership of Celebert on November 25, 2025, which is expected to have an insignificant effect on 2025 figures [7]

Core Insights - Novartis will present over 70 abstracts at the upcoming ASH and SABCS meetings, highlighting advancements in hematology and oncology, including 11 oral presentations and a late-breaker abstract for the Phase III VAYHIT2 trial of ianalumab in immune thrombocytopenia (ITP) [1][2][3] Hematology Highlights - The pivotal Phase III trial results for ianalumab in ITP patients previously treated with corticosteroids will be presented as a late-breaker [3] - Scemblix (asciminib) shows continued improvement in patient-reported outcomes compared to investigator-selected tyrosine kinase inhibitors in newly diagnosed chronic myeloid leukemia (CML) [2][3] - The 96-week data from the Phase III MANIFEST-2 study of pelabresib plus ruxolitinib in myelofibrosis represents the longest follow-up in a randomized combination trial [3] Oncology Highlights - Kisqali (ribociclib) data from the MONALEESA studies indicate long-term benefits for early and metastatic breast cancer patients [3] - The pooled analysis of patients treated with first-line ribociclib plus endocrine therapy shows long-term progression-free survival [5] - Five-year analysis of distant disease-free survival from the NATALEE trial of ribociclib plus a nonsteroidal aromatase inhibitor in HR+/HER2− early breast cancer patients will be presented [5] Product Information - Novartis has a strong legacy in hematology, having delivered over 10 medicines for more than 15 blood cancers and serious blood disorders over the past two decades [7][8] - The company has been at the forefront of scientific advancements in breast cancer for over 30 years, leading in the discovery of new therapies and combinations [9]

Core Insights - ABN AMRO has agreed to sell its personal loan subsidiary Alfam to Rabobank, while continuing to offer personal loans through a third-party arrangement with Rabobank [1][2] Company Summary - The personal loans market is highly competitive, making scale increasingly important; the partnership with Rabobank is expected to enhance service quality for clients [2] - The transaction is projected to positively impact ABN AMRO's CET1 capital ratio by approximately 5 basis points, with an estimated reduction of €1.2 billion in risk-weighted assets (RWA) and an anticipated book loss of around €100 million [3] - The closing of the transaction is expected in Q3 2026, pending regulatory approvals and works council consultation [3]

Core Viewpoint - ABN AMRO has unveiled a new strategy aimed at achieving profitable growth and setting financial targets for 2028, focusing on enhancing value for stakeholders through three strategic priorities: accelerating growth, right-sizing the cost base, and optimizing capital allocation [1][2][6]. Strategic Priorities - The bank plans to accelerate profitable growth by strengthening its position in Dutch retail banking and investing in digital innovations and challenger brands [6][9]. - A significant reduction in the workforce by 5,200 FTEs is planned by 2028 compared to 2024, with a commitment to support affected employees through a robust social plan [4][17]. - Capital will be reallocated to higher-return segments, with a reduction of €10 billion in risk-weighted assets in the Corporate Bank [11]. Financial Targets for 2028 - ABN AMRO aims for a return on equity (ROE) of at least 12% and a cost/income ratio below 55% [7][8]. - The bank targets an income exceeding €10 billion and a CET1 ratio above 13.75% [8]. Long-term Ambitions - The bank seeks to become a top-five private bank in Europe and strengthen its position in Dutch retail banking [3]. - ABN AMRO will support key European transitions in digitalization, energy, mobility, and defense [3]. Leadership and Organizational Changes - The leadership team is set for continuity, with key executives nominated for a second term to ensure ownership of the strategic plans [12]. - The organizational structure is being simplified to enhance efficiency, with a focus on reducing legal entities and optimizing processes through technology [17]. Strategic Partnership - ABN AMRO has agreed to sell its personal loan business, Alfam, to Rabobank, while continuing to offer personal loans through a third-party arrangement [13].

Core Viewpoint - Sanoma has updated its financial targets, aiming for high single-digit growth in adjusted operating profit from 2026 to 2030, driven by accelerated net sales and earnings growth in its Learning and Media Finland segments [1][2]. Group Financial Targets - The financial targets for Learning include mid single-digit growth in comparable net sales and high single-digit growth in adjusted operating profit [4]. - For Media Finland, the targets are stable comparable net sales and low single-digit growth in adjusted operating profit [4]. Growth Drivers - In Learning, curriculum renewals in key markets like Poland and Spain are expected to enhance organic net sales growth from 2026 to 2030, alongside a shift towards personalized learning and AI integration [2]. - Media Finland is set to benefit from a digital transformation and significant advertising growth, particularly with the anticipated opening of the gambling market in 2027 [3][6]. Financial Metrics - The Group's net debt to adjusted EBITDA target has been revised to below 2.5 from below 3.0 [3][5]. - The updated dividend policy aims for an increasing dividend, representing 40-60% of annual free cash flow [5][9]. Changes in Performance Measures - Sanoma will amend the definition of free cash flow to include lease liabilities, which will better reflect cash available for profit distribution [8][9]. - The payout ratio for dividends is expected to increase, with the 2024 payout ratio projected at 56% under the new definition, compared to 44% previously [9].

Core Insights - The European Commission has approved Dupixent (dupilumab) as the first targeted treatment for moderate-to-severe chronic spontaneous urticaria (CSU) in over a decade, providing a new option for patients aged 12 and older who have not responded adequately to antihistamines [1][4][5] Company Overview - Dupixent is developed jointly by Sanofi and Regeneron, targeting type 2 inflammation by inhibiting interleukin-4 (IL4) and interleukin-13 (IL13) pathways, which are key drivers of CSU [10][12] - The approval is based on the LIBERTY-CUPID phase 3 clinical studies, which demonstrated significant efficacy in reducing itch and hives compared to placebo [2][7][8] Clinical Study Findings - Two phase 3 studies (Study A and Study C) involved 284 patients aged 12 years and older, showing Dupixent significantly reduced urticaria activity and increased the percentage of patients achieving well-controlled disease at 24 weeks [2][7][8] - Study B provided additional safety data for patients who were inadequate responders or intolerant to anti-IgE therapy, confirming Dupixent's efficacy in this subgroup [2][3][7] Market Potential - Approximately 270,000 adults and adolescents in the EU suffer from CSU that remains symptomatic despite standard antihistamine treatment, indicating a significant market opportunity for Dupixent [5][6] - Dupixent is already approved for several chronic inflammatory diseases in over 60 countries, with more than 1.3 million patients treated globally [11][12]

Core Insights - Vivoryon Therapeutics N.V. will report its Q3 2025 financial results and operational progress on December 4, 2025 [1] - The company focuses on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases [3] Financial Results Announcement - The financial results for the period ending September 30, 2025, will be published on December 4, 2025 [1] - A conference call and webcast will be held to discuss these results, open to the public [1][2] Conference Call Details - The conference call is scheduled for December 4, 2025, at 3:00 pm CET / 9:00 am EST [2] - Participants can join via phone or webcast, with pre-registration recommended for phone access [2] Company Overview - Vivoryon is a clinical stage biotechnology company focused on innovative small molecule-based medicines for treating inflammatory and fibrotic disorders of the kidney [3] - The company's leading program, varoglutamstat, is a first-in-class orally available QPCT/L inhibitor aimed at treating diabetic kidney disease [3]

Core Points - The Global Panda Partners Conference 2025 was held in Chengdu, China, focusing on giant panda conservation and global ecological protection [1][5] - The conference gathered over 600 participants from more than 30 countries to discuss ecological development and cultural exchanges [1][5] Group 1: Giant Panda Conservation - The giant panda's threat level has been downgraded from "Endangered" to "Vulnerable" due to collaborative conservation efforts [2] - The captive giant panda population has reached 808, indicating a sustainable species status [4] Group 2: Ecological Civilization - The conference emphasized the importance of ecological civilization and China's commitment to harmonious development between nature and human activities [3] - The establishment of the Giant Panda National Park and relevant laws has optimized panda habitats significantly [4] Group 3: International Cooperation - The conference served as a platform for international dialogue on ecological protection and cultural exchange [5][6] - Participants engaged in various forums and activities to promote consensus on green development globally [6] Group 4: Venue and Local Significance - Shuangliu District, the conference venue, is recognized for its rapid economic growth and cultural heritage, contributing to its reputation as "China's happiest district" [7]